1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Sage/Biogen Depression Data Likely To Prolong Commercial Debate

 
• By Alaric DeArment

Data from the Phase III CORAL study of zuranolone showed the drug missing efficacy at day 15, which may dampen its appeal in the real-world setting.

DEPRESSION miserable depressed , Depression and its consequences, Depressed emotions concept , alone in depression - Image
Sage/Biogen announced results from the Phase III CORAL study of zuranolone in major depressive disorder • Source: Shutterstock

Debate over the commercial viability of Sage Therapeutics, Inc./Biogen, Inc.’s zuranolone isn’t getting any quieter as additional data rolls in. The Phase III CORAL study in major depressive disorder (MDD) met its primary endpoint of rapid onset of anti-depressant effect, with an acceptable safety and tolerability profile, but missed a key endpoint on durability.

The companies unveiled the CORAL data on 16 February, saying that the trial met its primary endpoint of a rapid and statistically significant reduction in depressive symptoms at day 3...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.